Medpace Holdings, Inc. 4

President & CEO August J. Troendle sold a total of 15,978 shares of Medpace Holdings, Inc. (MEDP) common stock in two open-market transactions on August 21 and 24, 2026.

On August 21 and August 24, 2026, Medpace Holdings, Inc. President & CEO August J. Troendle sold a total of 15,978 shares of Medpace common stock in open-market transactions pursuant to a pre-placed limit order during an open trading window. The first transaction on August 21 involved the sale of 13,995 shares at a weighted average price of $624.45 per share, and the second on August 24 involved the sale of 1,983 shares at a weighted average price of $620.23 per share, with each reported price reflecting multiple trades within disclosed intraday price ranges. Following these direct sales, Troendle’s direct ownership decreased modestly to 545,217 shares, while he also continues to indirectly beneficially own 4,733,019 additional shares held through Medpace Investors, LLC, for which he serves as sole manager and controlling unitholder, though he disclaims beneficial ownership beyond his pecuniary interest.

Filing Facts

CIK

1668397

Ticker

MEDP

Form

4

Source Type

fda

Accession

0000892251-26-000152

Alert Tier

6